Sector Update: Healthcare

Shutterstock photo

Healthcare shares today are mixed in pre-market trade. Shares of Agenus Inc. ( AGEN ) soared in Thursday's premarket session, bouncing off a 52-week low hit Wednesday, as the biotechnology company focused on treatments for cancers and infectious diseases released top-line results showing a Phase 2 study of HerpV, a vaccine candidate for the treatment of patients with herpes simplex virus-2, met its primary endpoint.

The shares were up 27% at $3.05 in recent premarket trading. They have a 52-week range of $2.40 to $5.40, with the low end of that range set Wednesday.

And, NovaBay Pharmaceuticals, Inc. ( NBY ), a clinical-stage biopharmaceutical company developing non-antibiotic antimicrobial products, said the auriclosene Phase 2b clinical study of impetigo has been completed.

NBY is down 51% at $0.82 per share, hitting a new 52-week low.

While the study showed that auriclosene is safe and well tolerated, it did not meet its primary clinical endpoint. NovaBay and its partner Galderma are examining the results from this study and expect to use the findings to guide the future course of the clinical development for auriclosene. NovaBay expects to provide an update in the near future.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing , Commodities
Referenced Symbols: AGEN , NBY

More from MT Newswires


MT Newswires

MT Newswires

Market News, Commodities

Research Brokers before you trade

Want to trade FX?

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com